Relationship of incomplete inhibition of PI3K pathway signaling and efficacy of cetuximab in KRAS wild-type colorectal cancers.

被引：0
|
作者：
Corcoran, Ryan Bruce
Ebi, Hiromichi
Ryan, David P.
Meyerhardt, Jeffrey A.
Engelman, Jeffrey A.
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.462
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
462
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Relationship of EGFR-independent activation of PI3K in KRAS wild-type colorectal cancers and cetuximab resistance
    Corcoran, Ryan Bruce
    Ebi, Hiromichi
    Ryan, David P.
    Meyerhardt, Jeffrey A.
    Engelman, Jeffrey A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [2] Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
    Temraz, Sally
    Mukherji, Deborah
    Shamseddine, Ali
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (09): : 22976 - 22988
  • [3] Inhibition of wildtype PI3Kα signaling is required for durable efficacy in PI3Kα mutant cancer cells due to robust reactivation of wild-type PI3Kα signaling
    MacDougall, John R.
    Zhong, Mengqi
    Merritt, Hanne
    Del Cid, Joselyn S.
    Bradley, John
    Mak, Raymond
    Dhawan, Neil
    Chen, Wei
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Calmodulin and PI3K Signaling in KRAS Cancers
    Nussinov, Ruth
    Wang, Guanqiao
    Tsai, Chung-Jung
    Jang, Hyunbum
    Lu, Shaoyong
    Banerjee, Avik
    Zhang, Jian
    Gaponenko, Vadim
    TRENDS IN CANCER, 2017, 3 (03): : 214 - 224
  • [5] Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway
    Liu, Yanfei
    Tian, Shifeng
    Yi, Ben
    Feng, Zhiqiang
    Chu, Tianhao
    Liu, Jun
    Zhang, Chunze
    Zhang, Shiwu
    Wang, Yijia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
    Roper, Jatin
    Sinnamon, Mark J.
    Coffee, Erin M.
    Belmont, Peter
    Keung, Lily
    Georgeon-Richard, Larissa
    Wang, Wei Vivian
    Faber, Anthony C.
    Yun, Jihye
    Yilmaz, Oemer H.
    Bronson, Roderick T.
    Martin, Eric S.
    Tsichlis, Philip N.
    Hung, Kenneth E.
    CANCER LETTERS, 2014, 347 (02) : 204 - 211
  • [7] Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS
    Tural, Deniz
    Batur, Sebnem
    Erdamar, Sibel
    Akar, Emre
    Kepil, Nuray
    Mandel, Nil Molinas
    Serdengecti, Suheyla
    TUMOR BIOLOGY, 2014, 35 (02) : 1041 - 1049
  • [8] Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers
    Sang-A Kim
    Hyejoo Park
    Kui-Jin Kim
    Ji-Won Kim
    Ji Hea Sung
    Milang Nam
    Ju Hyun Lee
    Eun Hee Jung
    Koung Jin Suh
    Ji Yun Lee
    Se Hyun Kim
    Jeong-Ok Lee
    Jin Won Kim
    Yu Jung Kim
    Jee Hyun Kim
    Soo-Mee Bang
    Jong Seok Lee
    Keun-Wook Lee
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2995 - 3005
  • [9] Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers
    Kim, Sang-A
    Park, Hyejoo
    Kim, Kui-Jin
    Kim, Ji-Won
    Sung, Ji Hea
    Nam, Milang
    Lee, Ju Hyun
    Jung, Eun Hee
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Se Hyun
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong Seok
    Lee, Keun-Wook
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 2995 - 3005
  • [10] Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma
    Zhang, Yanping
    Peng, Guangyong
    Hsueh, Eddy C.
    CANCER RESEARCH, 2016, 76
12345